Buprenorphine Treatment in Pregnancy and Maternal-Infant Outcomes

作者：Sunaya R. Krishnapura, Elizabeth McNeer, Sarah F. Loch, Thomas S. Reese, Judith A. Dudley, Julia C. Phillippi, Andrew Wiese, William D. Dupont, Ashley A. Leech, Stephen W. Patrick · 发表于：JAMA Health Forum · 年份：2025 · DOI：10.1001/jamahealthforum.2025.1814 · 被引用次数：7 · 研究领域：Prenatal Substance Exposure Effects、Maternal Mental Health During Pregnancy and Postpartum、Opioid Use Disorder Treatment

Importance: Opioid use disorder (OUD) in pregnancy has grown in the US. Buprenorphine, a medication to treat OUD, may improve pregnancy outcomes; however, most pregnant individuals do not receive it. Research evaluating buprenorphine use in pregnancy, its effects on the maternal-infant dyad, and in comparison to no treatment is limited. Objective: To determine if treatment with buprenorphine for opioid use disorder in pregnancy is associated with improved maternal and infant outcomes compared to no treatment among mothers with OUD. Design, Setting, and Participants: This retrospective cohort study included maternal-infant dyads continuously enrolled in the Tennessee Medicaid program from 20 weeks' estimated gestational age to 6 weeks post partum between 2010 and 2021. Medicaid administrative was linked to birth and death certificates. Data analysis was conducted from April to October 2024. Exposure: Buprenorphine use during pregnancy. Main Outcomes and Measures: Adverse pregnancy outcomes included preterm birth, neonatal intensive care unit (NICU) admission, infant death, severe maternal morbidity (SMM), intensive care unit admission, and maternal death. Logistic regression and propensity scores with overlap weighting were used to calculate adjusted predicted probabilities for adverse outcomes. Results: Among 14 463 maternal-infant dyads, 7469 (51.6%) received buprenorphine treatment (median [IQR] maternal age, 27 [24-31] years). There was a statistically significant lower ra...